These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36268393)

  • 41. A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases.
    Padwale V; Kirnake V; Daswani R; Kodmalwar A; Gupta A
    Cureus; 2024 Jul; 16(7):e64777. PubMed ID: 39156336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness'.
    Shinozaki S; Osawa H; Miura Y; Hayashi Y; Sakamoto H; Yano T; Kawarai Lefor A; Yamamoto H
    Biomed Rep; 2022 Jun; 16(6):51. PubMed ID: 35620314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
    Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
    Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world outcomes associated with vonoprazan-based
    Howden CW; Cook EE; Swallow E; Yang K; Guo H; Pelletier C; Jacob R; Sugano K
    Therap Adv Gastroenterol; 2023; 16():17562848231168714. PubMed ID: 37153499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P-CAB
    Jiang Y; Zhang R; Fang Y; Zhao R; Fu Y; Ren P; Zhan Q; Shao M
    Therap Adv Gastroenterol; 2024; 17():17562848241241223. PubMed ID: 38751605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for
    Lyu QJ; Pu QH; Zhong XF; Zhang J
    Biomed Res Int; 2019; 2019():9781212. PubMed ID: 31211144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The presence of hiatal hernia is a significant predictor for symptomatic recurrence after cessation of vonoprazan therapy for gastroesophageal reflux disease: a long-term observational study.
    Shinozaki S; Osawa H; Miura Y; Sakamoto H; Hayashi Y; Yano T; Despott EJ; Yamamoto H
    Scand J Gastroenterol; 2024 Aug; 59(8):893-899. PubMed ID: 38821110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vonoprazan a novel potassium competitive acid blocker; another leap forward.
    Elsabaawy M; Shaban A; Al-Arab AE; Elbahr O; Edrees A; Afify S
    Prz Gastroenterol; 2024; 19(2):135-142. PubMed ID: 38939071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of
    Mori N; Nishiura Y; Suga D; Moritani I; Yamanaka Y; Ooya Y; Inoue H; Takase K; Hioki M; Shiraki K
    Biomed Rep; 2018 Aug; 9(2):169-174. PubMed ID: 30013779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of
    Furuta T; Yamade M; Higuchi T; Takahashi S; Ishida N; Tani S; Tamura S; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs.
    Tanaka H; Takeuchi T; Nishida S; Hongo H; Takii M; Higashino T; Sanomura M; Miyazaki H; Hoshimoto M; Kimura T; Sakaguchi M; Abe T; Hakoda A; Sugawara N; Iwatsubo T; Kawaguchi S; Ota K; Kojima Y; Higuchi K
    Digestion; 2023; 104(4):270-282. PubMed ID: 36649678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-Line
    Sue S; Suzuki N; Shibata W; Sasaki T; Yamada H; Kaneko H; Tamura T; Ishii T; Kondo M; Maeda S
    Gastroenterol Res Pract; 2017; 2017():2019802. PubMed ID: 29181022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
    Saito Y; Konno K; Sato M; Nakano M; Kato Y; Saito H; Serizawa H
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
    Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
    Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM; Syam AF; Lee YY
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial.
    Chen C; Zhang D; Huang S; Zeng F; Li D; Zhang X; Chen R; Chen S; Wang J; Bai F
    BMC Gastroenterol; 2024 Apr; 24(1):131. PubMed ID: 38609893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
    Kakiuchi T; Matsuo M; Endo H; Sakata Y; Esaki M; Noda T; Imamura I; Hashiguchi K; Ogata S; Fujioka Y; Hanada K; Fukuda K; Yoshimura M; Kajiwara T; Yamamoto K; Yamaguchi D; Kawakubo H; Matsunaga T; Sumino M; Matsunaga K; Muro E; Watanabe A; Fujimoto K
    J Gastroenterol; 2023 Mar; 58(3):196-204. PubMed ID: 36528706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potassium-Competitive Acid Blocker and Proton Pump Inhibitor-Based Regimens for First-Line
    Malfertheiner P; Moss SF; Daniele P; Pelletier C; Jacob R; Tremblay G; Hubscher E; Leifke E; Chey WD
    Gastro Hep Adv; 2022; 1(5):824-834. PubMed ID: 39131848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study.
    Pattarapuntakul T; Wong T; Wetwittayakhlang P; Netinatsunton N; Keeratichananont S; Kaewdech A; Jandee S; Chamroonkul N; Sripongpun P; Lakatos PL
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.